[Skip to Content]
[Skip to Content Landing]
Other Articles
December 10, 1949


Author Affiliations

New York

From the Surgical Service of Harlem Hospital.

JAMA. 1949;141(15):1047-1050. doi:10.1001/jama.1949.02910150013005

Duggar1 and associates of the Lederle Laboratories Division, American Cyanamid Company, introduced aureomycin, a new and versatile antibiotic which is derived from a strain of streptomyces. It has shown a wide range of activity against many infections, and the literature is beginning to contain many reports of the different diseases in human beings against which it is useful.

It was first employed in the treatment of human beings while we were carrying on a study of lymphogranuloma venereum2 which was started in January 1948. During that study it occurred to one of us (L. T. W.) that it might be effective in the treatment of granuloma inguinale, and it was accordingly used in 3 cases which were described in our previous report.3 We were both surprised and pleased over the rapid and favorable results obtained with amazingly small doses of the drug, and we decided to continue